Cargando…

Artificial intelligence–enabled clinical trials might be a faster way to perform rapid clinical trials and counter future pandemics: lessons learned from the COVID-19 period

Detalles Bibliográficos
Autores principales:	Chakraborty, Chiranjib, Bhattacharya, Manojit, Dhama, Kuldeep, Agoramoorthy, Govindasamy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10389411/ https://www.ncbi.nlm.nih.gov/pubmed/36906740 http://dx.doi.org/10.1097/JS9.0000000000000088

Ejemplares similares

Hybrid immunity against COVID-19 in different countries with a special emphasis on the Indian scenario during the Omicron period
por: Bhattacharya, Manojit, et al.
Publicado: (2022)

Natural selection of the D614G mutation in SARS-CoV-2 Omicron (B.1.1.529) variant and its subvariants
por: Chakraborty, Chiranjib, et al.
Publicado: (2023)

The Drug Repurposing for COVID-19 Clinical Trials Provide Very Effective Therapeutic Combinations: Lessons Learned From Major Clinical Studies
por: Chakraborty, Chiranjib, et al.
Publicado: (2021)

Omicron variant (B.1.1.529) of SARS-CoV-2: understanding mutations in the genome, S-glycoprotein, and antibody-binding regions
por: Bhattacharya, Manojit, et al.
Publicado: (2022)

A comprehensive analysis of the mutational landscape of the newly emerging Omicron (B.1.1.529) variant and comparison of mutations with VOCs and VOIs
por: Chakraborty, Chiranjib, et al.
Publicado: (2022)

SARS-CoV-2 Vaccines, Vaccine Development Technologies, and Significant Efforts in Vaccine Development during the Pandemic: The Lessons Learned Might Help to Fight against the Next Pandemic
por: Chakraborty, Chiranjib, et al.
Publicado: (2023)

Appearance and re-appearance of zoonotic disease during the pandemic period: long-term monitoring and analysis of zoonosis is crucial to confirm the animal origin of SARS-CoV-2 and monkeypox virus
por: Chakraborty, Chiranjib, et al.
Publicado: (2022)

Integrative Bioinformatics Approaches Indicate a Particular Pattern of Some SARS-CoV-2 and Non-SARS-CoV-2 Proteins
por: Chakraborty, Chiranjib, et al.
Publicado: (2022)

Recently spreading human monkeypox virus infection and its transmission during COVID-19 pandemic period: A travelers' prospective
por: Bhattacharya, Manojit, et al.
Publicado: (2022)

Cases of BA.2.75 and recent BA.2.75.2 subvariant of Omicron are increasing in India: Is it alarming at the global level?
por: Chakraborty, Chiranjib, et al.
Publicado: (2022)

A call for a novel and next-generation vaccine against monkeypox disease
por: Bhattacharya, Manojit, et al.
Publicado: (2022)

D614G mutation and SARS-CoV-2: impact on S-protein structure, function, infectivity, and immunity
por: Bhattacharya, Manojit, et al.
Publicado: (2021)

A Detailed Overview of SARS-CoV-2 Omicron: Its Sub-Variants, Mutations and Pathophysiology, Clinical Characteristics, Immunological Landscape, Immune Escape, and Therapies
por: Chatterjee, Srijan, et al.
Publicado: (2023)

Evolution, Mode of Transmission, and Mutational Landscape of Newly Emerging SARS-CoV-2 Variants
por: Chakraborty, Chiranjib, et al.
Publicado: (2021)

The current second wave and COVID-19 vaccination status in India
por: Chakraborty, Chiranjib, et al.
Publicado: (2021)

All Nations Must Prioritize the COVID-19 Vaccination Program for Elderly Adults Urgently
por: Chakraborty, Chiranjib, et al.
Publicado: (2021)

SARS-CoV-2 Brazil variants in Latin America: More serious research urgently needed on public health and vaccine protection
por: Chakraborty, Chiranjib, et al.
Publicado: (2021)

Asian-Origin Approved COVID-19 Vaccines and Current Status of COVID-19 Vaccination Program in Asia: A Critical Analysis
por: Chakraborty, Chiranjib, et al.
Publicado: (2021)

A Paradigm Shift in the Combination Changes of SARS-CoV-2 Variants and Increased Spread of Delta Variant (B.1.617.2) across the World
por: Chakraborty, Chiranjib, et al.
Publicado: (2022)

Monkeypox in South-East Asia: Is an alarming bell for this region? – Correspondence
por: Chakraborty, Chiranjib, et al.
Publicado: (2022)

The current landscape of long COVID clinical trials: NIH’s RECOVER to Stanford Medicine’s STOP-PASC initiative
por: Chakraborty, Chiranjib, et al.
Publicado: (2023)

Recombinant SARS-CoV-2 variants XD, XE, and XF: The emergence of recombinant variants requires an urgent call for research – Correspondence
por: Chakraborty, Chiranjib, et al.
Publicado: (2022)

Evolution, epidemiology, geographical distribution, and mutational landscape of newly emerging monkeypox virus
por: Chakraborty, Chiranjib, et al.
Publicado: (2022)

Monkeypox virus vaccine evolution and global preparedness for vaccination
por: Chakraborty, Chiranjib, et al.
Publicado: (2022)

Evaluation of differentially expressed genes during replication using gene expression landscape of monkeypox-infected MK2 cells: A bioinformatics and systems biology approach to understanding the genomic pattern of viral replication
por: Chakraborty, Chiranjib, et al.
Publicado: (2023)

Quantum computing on nucleic acid research: Approaching towards next-generation computing
por: Chakraborty, Chiranjib, et al.
Publicado: (2023)

D614G mutation eventuates in all VOI and VOC in SARS-CoV-2: Is it part of the positive selection pioneered by Darwin?
por: Chakraborty, Chiranjib, et al.
Publicado: (2021)

Structural Landscape of nsp Coding Genomic Regions of SARS-CoV-2-ssRNA Genome: A Structural Genomics Approach Toward Identification of Druggable Genome, Ligand-Binding Pockets, and Structure-Based Druggability
por: Chakraborty, Chiranjib, et al.
Publicado: (2022)

A novel mutation-proof, next-generation vaccine to fight against upcoming SARS-CoV-2 variants and subvariants, designed through AI enabled approaches and tools, along with the machine learning based immune simulation: A vaccine breakthrough
por: Bhattacharya, Manojit, et al.
Publicado: (2023)

Organ-on-chip: a new paradigm for clinical trials – correspondence
por: Chopra, Hitesh, et al.
Publicado: (2023)

Designing, characterization, and immune stimulation of a novel multi-epitopic peptide-based potential vaccine candidate against monkeypox virus through screening its whole genome encoded proteins: An immunoinformatics approach
por: Bhattacharya, Manojit, et al.
Publicado: (2022)

Stem cells in the light of evolution
por: Chakraborty, Chiranjib, et al.
Publicado: (2012)

India’s cost-effective COVID-19 vaccine development initiatives
por: Chakraborty, Chiranjib, et al.
Publicado: (2020)

Can the RBD mutation R346X provide an additional fitness to the “variant soup,” including offspring of BQ and XBB of SARS-CoV-2 Omicron for the antibody resistance?
por: Chatterjee, Srijan, et al.
Publicado: (2023)

Resistance to nirmatrelvir due to mutations in the Mpro in the subvariants of SARS-CoV-2 Omicron: Another concern?
por: Chatterjee, Srijan, et al.
Publicado: (2023)

Molnupiravir’s mechanism of action drives “error catastrophe” in SARS-CoV-2: A therapeutic strategy that leads to lethal mutagenesis of the virus
por: Chatterjee, Srijan, et al.
Publicado: (2023)

Recently emerged omicron subvariant BF.7 and its R346T mutation in the RBD region reveal increased transmissibility and higher resistance to neutralization antibodies: need to understand more under the current scenario of rising cases in China and fears of driving a new wave of the COVID-19 pandemic
por: Chakraborty, Chiranjib, et al.
Publicado: (2023)

Continent-wide evolutionary trends of emerging SARS-CoV-2 variants: dynamic profiles from Alpha to Omicron
por: Chakraborty, Chiranjib, et al.
Publicado: (2022)

Altered gut microbiota patterns in COVID-19: Markers for inflammation and disease severity
por: Chakraborty, Chiranjib, et al.
Publicado: (2022)

The SARS-CoV-2 Omicron recombinant subvariants XBB, XBB.1, and XBB.1.5 are expanding rapidly with unique mutations, antibody evasion, and immune escape properties – an alarming global threat of a surge in COVID-19 cases again?
por: Chakraborty, Chiranjib, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_hvaqqcb46mveidj7piba4869k6